Knight Therapeutics announces launch of Minjuvi in Mexico

Knight Therapeutics (KHTRF) announced the launch of Minjuvi by its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. Minjuvi in combination with lenalidomide, followed by Minjuvi monotherapy, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, who are not eligible for autologous stem cell transplantation. The marketing authorization approval was based on the data from L-MIND trial, an open label, multicenter, single arm Phase 2 study, that evaluated Minjuvi in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL ineligible for ASCT. The study primary analysis results demonstrated an objective response rate of 60%, including a complete response rate of 43% and a disease control rate of 74%. According to the 2025 National Comprehensive Cancer Network Guidelines, Minjuvi is listed as one of the preferred second-line treatments for DLBCL patients who are ineligible for transplantation. In September 2021, Knight entered into a supply and distribution agreement with Incyte (INCY), for the exclusive rights to distribute tafasitamab in Latin America. In October 2024, COFEPRIS, the Mexican health regulatory agency, granted regulatory approval through orphan medicine recognition for Minjuvi in Mexico.